Cipher Pharmaceuticals Inc.
https://www.cipherpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cipher Pharmaceuticals Inc.
UK's Cambridge Keen To Challenge US Counterpart With Biotech Start-Ups
Cambridge Innovation Capital partner Robert Tansley tells Scrip that the UK has "a really strong history of innovation in biological sciences and Cambridge has been at the forefront” but this has not equated to a substantial number of biotech companies “where we have lagged significantly behind the US."
Tech Transfer Roundup: Lysogene Elects Option On Gene Therapy Discovered At Weizmann Institute
French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.
Deal Watch: Lilly, Innovent Build On Long Alliance To Partner On Three Cancer Drugs
Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.
Novartis Bets Big On Next-Gen Gene Therapy With Voyager Pact
The Swiss giant has gained access to next-generation AAV capsids that could reach cells in the brain, something that has not been possible with technologies used to date.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Innocutis Medical LLC (Innocutis Holding LLC
- JSJ Pharmaceuticals)
- Cipher Pharmaceuticals US LLC